$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000093976716000266 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$77.58M	$62.19M	$9.854M
YoY Change	680.65%	531.15%	56.64%
Cost Of Revenue	$1.900M	$2.455M	$1.420M
YoY Change	90.0%	72.89%	147.82%
Gross Profit	$50.06M	$40.29M	$8.434M
YoY Change	461.57%	377.67%	47.5%
Gross Profit Margin	64.53%	64.78%	85.59%
Selling, General & Admin	$13.00M	$32.46M	$17.84M
YoY Change	-23.98%	81.95%	80.11%
% of Gross Profit	25.97%	80.58%	211.55%
Research & Development	$23.80M	$20.26M	$26.09M
YoY Change	1.28%	-22.36%	-40.2%
% of Gross Profit	47.54%	50.28%	309.35%
Depreciation & Amortization	$200.0K	$300.0K	$400.0K
YoY Change	-33.33%	-25.0%	-78.95%
% of Gross Profit	0.4%	0.74%	4.74%
Operating Expenses	$36.70M	$54.93M	$45.64M
YoY Change	-9.61%	20.37%	-21.14%
Operating Profit	$38.88M	$7.264M	-$35.78M
YoY Change	-223.05%	-120.3%	-30.62%
Interest Expense	-$3.600M	$7.834M	$10.04M
YoY Change	-63.64%	-21.95%	-18.28%
% of Operating Profit	-9.26%	107.85%
Other Income/Expense, Net		-$18.55M	-$9.761M
YoY Change		90.02%	-11.15%
Pretax Income	$35.10M	-$11.28M	-$45.50M
YoY Change	-184.58%	-75.2%	-27.32%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	$35.12M	-$11.28M	-$45.54M
YoY Change	-184.5%	-75.22%	-27.2%
Net Earnings / Revenue	45.27%	-18.14%	-462.17%
Basic Earnings Per Share	$0.12	-$0.04
Diluted Earnings Per Share	$0.12	-$0.04	-$209.1K
COMMON SHARES
Basic Shares Outstanding	286.5M shares	256.3M shares	225.4M shares
Diluted Shares Outstanding		256.3M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$419.8M	$319.7M	$197.8M
YoY Change	151.23%	61.63%	3.02%
Cash & Equivalents	$151.7M	$111.2M	$145.6M
Short-Term Investments	$268.1M	$208.5M	$52.20M
Other Short-Term Assets	$5.400M	$7.100M	$3.900M
YoY Change	42.11%	82.05%	-80.6%
Inventory	$3.338M	$3.292M	$2.121M
Prepaid Expenses
Receivables	$40.40M	$91.20M	$3.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$469.0M	$421.3M	$207.4M
YoY Change	162.5%	103.2%	-6.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.071M	$1.737M	$1.448M
YoY Change	44.42%	19.96%	-50.55%
Goodwill	$63.68M	$63.68M	$63.68M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$55.60M	$55.80M	$81.60M
YoY Change	-33.49%	-31.62%	-3.55%
Other Assets	$1.232M	$1.774M	$6.508M
YoY Change	-46.64%	-72.74%	-8.35%
Total Long-Term Assets	$126.7M	$127.2M	$155.9M
YoY Change	-17.53%	-18.43%	-4.35%
TOTAL ASSETS
Total Short-Term Assets	$469.0M	$421.3M	$207.4M
Total Long-Term Assets	$126.7M	$127.2M	$155.9M
Total Assets	$595.7M	$548.5M	$363.2M
YoY Change	79.25%	51.0%	-5.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.565M	$3.965M	$2.256M
YoY Change	2.56%	75.75%	-32.9%
Accrued Expenses	$53.40M	$69.40M	$29.79M
YoY Change	195.5%	132.98%	-33.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$189.1M	$109.4M	$450.0K
YoY Change		24203.33%	-99.54%
Total Short-Term Liabilities	$268.8M	$201.6M	$55.92M
YoY Change	414.41%	260.58%	-67.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$81.49M	$377.4M
YoY Change	-100.0%	-78.41%	46.31%
Other Long-Term Liabilities	$541.0K	$759.0K	$1.881M
YoY Change	-81.72%	-59.65%	-60.58%
Total Long-Term Liabilities	$541.0K	$82.25M	$379.3M
YoY Change	-99.87%	-78.32%	44.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$268.8M	$201.6M	$55.92M
Total Long-Term Liabilities	$541.0K	$82.25M	$379.3M
Total Liabilities	$506.4M	$516.5M	$437.5M
YoY Change	7.03%	18.06%	-1.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.983B	-$2.018B	-$1.893B
YoY Change	3.67%	6.6%	10.77%
Common Stock	$290.0K	$286.0K	$225.0K
YoY Change	27.19%	27.11%	15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$89.32M	$32.00M	-$74.20M
YoY Change
Total Liabilities & Shareholders Equity	$595.7M	$548.5M	$363.2M
YoY Change	79.25%	51.0%	-5.32%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	$35.12M	-$11.28M	-$45.54M
YoY Change	-184.5%	-75.22%	-27.2%
Depreciation, Depletion And Amortization	$200.0K	$300.0K	$400.0K
YoY Change	-33.33%	-25.0%	-78.95%
Cash From Operating Activities	$85.10M	-$5.800M	-$34.30M
YoY Change	-340.4%	-83.09%	-40.86%
INVESTING ACTIVITIES
Capital Expenditures	-$600.0K	$0.00	$0.00
YoY Change	100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$58.30M	-$12.10M	-$31.50M
YoY Change	-339.92%	-61.59%	-381.25%
Cash From Investing Activities	-$58.90M	-$12.10M	-$31.50M
YoY Change	-345.42%	-61.59%	-381.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$145.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	15.80M	-700.0K	149.4M
YoY Change	113.51%	-100.47%	-49900.0%
NET CHANGE
Cash From Operating Activities	85.10M	-5.800M	-34.30M
Cash From Investing Activities	-58.90M	-12.10M	-31.50M
Cash From Financing Activities	15.80M	-700.0K	149.4M
Net Change In Cash	42.00M	-18.60M	83.60M
YoY Change	-1150.0%	-122.25%	-277.49%
FREE CASH FLOW
Cash From Operating Activities	$85.10M	-$5.800M	-$34.30M
Capital Expenditures	-$600.0K	$0.00	$0.00
Free Cash Flow	$85.70M	-$5.800M	-$34.30M
YoY Change	-344.16%	-83.09%	-40.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	286455917	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
	dei	Trading Symbol TradingSymbol	exel
CY2015Q4	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	18071000	USD
CY2016Q3	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	14887000	USD
CY2015Q4	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	10938000	USD
CY2016Q3	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	18710000	USD
CY2015Q3	exel	Allowanceforcustomerreturns Allowanceforcustomerreturns	0	USD
CY2015Q4	exel	Allowanceforcustomerreturns Allowanceforcustomerreturns	0	USD
CY2016Q3	exel	Allowanceforcustomerreturns Allowanceforcustomerreturns	400000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	253310000	USD
CY2016Q3	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	379648000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	253433000	USD
CY2016Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	379621000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	7000	USD
CY2016Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	98000	USD
CY2015Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	130000	USD
CY2016Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	71000	USD
	exel	Debt Collateral Number Of Affiliate Banks DebtCollateralNumberOfAffiliateBanks	1	affiliate
	exel	Debt Collateral Number Of Required Investment Accounts DebtCollateralNumberOfRequiredInvestmentAccounts	1	account
	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	-11757000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.35
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	366031000	USD
	exel	Increase Decrease Accrued Clinical Liabilities IncreaseDecreaseAccruedClinicalLiabilities	-3184000	USD
	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	8400000	USD
	exel	Increase Decreasein Accrued Collaboration Liability IncreaseDecreaseinAccruedCollaborationLiability	7772000	USD
	exel	Paymentsfor Conversionof Convertible Debt PaymentsforConversionofConvertibleDebt	0	USD
	exel	Paymentsfor Conversionof Convertible Debt PaymentsforConversionofConvertibleDebt	7134000	USD
CY2016Q2	exel	Periodfor Shipmentof Newly Approved Product Upon Approval PeriodforShipmentofNewlyApprovedProductUponApproval	P3D
	exel	Restructuring Reserve Proceedsfrom Saleof Property Plantand Equipment RestructuringReserveProceedsfromSaleofPropertyPlantandEquipment	34000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6401000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3965000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3629000	USD
CY2016Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	15986000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-232000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1489727000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1504052000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1591782000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1772123000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2050086000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12026000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15420000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3603000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18346000	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12442000	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19722000	USD
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22289000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	14274000	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17041000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8295000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120339000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65777000	shares
CY2015Q4	us-gaap	Assets Assets	332342000	USD
CY2016Q3	us-gaap	Assets Assets	548490000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	178665000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	421328000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	250687000	USD
CY2016Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	366058000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	250687000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	366058000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	98000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	130000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	71000	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	71000	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	67300000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	250810000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	55817000	USD
CY2016Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	310241000	USD
CY2016Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	37	investment
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80395000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145642000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141634000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111219000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	65247000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30415000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	293800000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	227960943	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	286123166	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	227960943	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	286123166	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	228000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	286000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-145289000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-237954000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-261564000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45409000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120096000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161855000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11493000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-105193000	USD
CY2015Q3	us-gaap	Contracts Revenue ContractsRevenue	3000000	USD
	us-gaap	Contracts Revenue ContractsRevenue	3000000	USD
CY2016Q3	us-gaap	Contracts Revenue ContractsRevenue	19452000	USD
	us-gaap	Contracts Revenue ContractsRevenue	30414000	USD
CY2015Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2016Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	29365000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	291828000	USD
CY2013Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	301550000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	223629000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	337937000	USD
CY2016Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	81493000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1420000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2872000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2455000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4700000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	285308000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18939000	USD
CY2016Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	91207000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	232573000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1063000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	754000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	549000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	95000	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	2494000	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13773000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13773000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	63684000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	63684000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1034000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	85923000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14293000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18816000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2583000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	251512000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-259000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	676000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1832000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-535000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1367000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-815000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1940000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3342000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-16754000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-2650000	USD
CY2012	us-gaap	Interest Expense InterestExpense	24778000	USD
CY2013	us-gaap	Interest Expense InterestExpense	38779000	USD
CY2014	us-gaap	Interest Expense InterestExpense	41362000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	10037000	USD
	us-gaap	Interest Expense InterestExpense	30501000	USD
CY2015	us-gaap	Interest Expense InterestExpense	40680000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	7834000	USD
	us-gaap	Interest Expense InterestExpense	28575000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	583000	USD
CY2016Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	582000	USD
CY2015Q4	us-gaap	Inventory Gross InventoryGross	3871000	USD
CY2016Q3	us-gaap	Inventory Gross InventoryGross	4012000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	2616000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	3292000	USD
CY2015Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1255000	USD
CY2016Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	720000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1037000	USD
CY2016Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	890000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2251000	USD
CY2016Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2540000	USD
CY2015Q3	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	900000	USD
CY2016Q3	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	476015000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	483452000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	482592000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	473148000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	516468000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	332342000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	548490000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	52251000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	201643000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	417937000	USD
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	190858000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	109365000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	417937000	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	81493000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	83600000	USD
CY2016Q3	us-gaap	Long Term Investments LongTermInvestments	55817000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	80000000	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	145331000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2641000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26068000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155638000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106152000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	122582000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-145335000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-238192000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-261297000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-45542000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-120176000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-161744000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-11284000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-105345000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22792000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-37556000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-37021000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9761000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30355000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-40268000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18548000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38338000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	80000000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	45635000	USD
	us-gaap	Operating Expenses OperatingExpenses	117055000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54930000	USD
	us-gaap	Operating Expenses OperatingExpenses	180880000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35781000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89821000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7264000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-67007000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13212000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19791000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2309000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1774000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	133000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	80000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-209000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	152000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2960000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	759000	USD
CY2016Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	81600000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1338000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1381000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	276000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	146000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3059000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4010000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1890000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	5939000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	4211000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	119692000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	258509000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1116000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2616000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	4150000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3806000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7148000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	145651000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	130341000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	100635000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-4381000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	95000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	2494000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2266000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1300000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	92000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3787000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9296000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	274000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	479000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1434000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1737000	USD
CY2015Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5183000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26091000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72879000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20256000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72166000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2650000	USD
CY2016Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4150000	USD
CY2016Q3	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	100000	USD
CY2015Q3	us-gaap	Restructuring Charges RestructuringCharges	282000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1142000	USD
CY2016Q3	us-gaap	Restructuring Charges RestructuringCharges	-244000	USD
	us-gaap	Restructuring Charges RestructuringCharges	871000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	4590000	USD
CY2016Q3	us-gaap	Restructuring Reserve RestructuringReserve	2225000	USD
	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	941000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1251692000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1489883000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1751180000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1912925000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2018270000	USD
CY2015Q3	us-gaap	Revenues Revenues	9854000	USD
	us-gaap	Revenues Revenues	27234000	USD
CY2016Q3	us-gaap	Revenues Revenues	62194000	USD
	us-gaap	Revenues Revenues	113873000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	157700000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6854000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24234000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	42742000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	83459000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17842000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40162000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32463000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	103143000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15420000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18346000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20042258	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	80516	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	307601	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3771250	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	221332000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27425854	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27448739	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.22
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.80
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.81
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.49
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.67
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	172458000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y0M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M29D
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	25426000	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	208462000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3360248	shares
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	238127000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14499000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-159323000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-140806000	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32022000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	217587000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	203153000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	256319000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	238024000	shares
	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">. Fiscal year 2016 will end on December 30, 2016, and fiscal year 2015, ended on January 1, 2016. For convenience, references in this report as of and for the fiscal periods ended September 30, 2016, and October 2, 2015, and as of and for the fiscal years ended December 30, 2016 and January 1, 2016, are indicated as being as of and for the periods ended September 30, 2016, September 30, 2015, </font><font style="font-family:Times New Roman;font-size:10pt;">and the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016, and December 31, 2015, respectively.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States that requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, including for deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances) </font><font style="font-family:Times New Roman;font-size:10pt;">and the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations</font><font style="font-family:inherit;font-size:10pt;">, recoverability of inventory, certain accrued liabilities including clinical trial and collaboration liability accruals, the valuation of the debt and equity components of our convertible debt and share-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font><font style="font-family:inherit;font-size:10pt;"> </font></div></div>

Files In Submission

Name	View Source	Status
0000939767-16-000266-index-headers.html	Edgar Link	pending
0000939767-16-000266-index.html	Edgar Link	pending
0000939767-16-000266.txt	Edgar Link	pending
0000939767-16-000266-xbrl.zip	Edgar Link	pending
exel-20160930.xml	Edgar Link	completed
exel-20160930.xsd	Edgar Link	pending
exel-20160930_cal.xml	Edgar Link	unprocessable
exel-20160930_def.xml	Edgar Link	unprocessable
exel-20160930_lab.xml	Edgar Link	unprocessable
exel-20160930_pre.xml	Edgar Link	unprocessable
exel2016093010-q.htm	Edgar Link	pending
exel20160930exhibit121.htm	Edgar Link	pending
exel20160930exhibit311.htm	Edgar Link	pending
exel20160930exhibit312.htm	Edgar Link	pending
exel20160930exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2016 Q4 Form 10-Q Financial Statement

#000093976716000266 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2016 Q4 Form 10-Q Financial Statement

#000093976716000266 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel